<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article330</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/RAVE" style="display:block; margin-bottom:10px;">RAVE Original</a></li>
<h2><strong>RAVE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis".<br/>
The New England Journal of Medicine. 2010. 363:221-232.<br/>
PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with ANCA-associated vasculitis, is rituximab as effective as cyclophosphamide for inducing remission?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Rituximab was not inferior to cyclophosphamide for inducing remission in patients with severe ANCA-associated vasculitis and may be superior in patients with relapsing disease.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, double-blind, double-dummy, noninferiority trial<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: ANCA-positive patients with Wegener's granulomatosis or microscopic polyangiitis and a BVAS/WG score of ≥3.<br/>
Exclusion Criteria: Severe alveolar hemorrhage requiring ventilatory support or advanced renal dysfunction (serum creatinine &gt;4.0 mg/dL).<br/>
Baseline Characteristics: Similar between two groups, including disease activity, organ involvement, and proportion of relapsing disease.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Rituximab group received intravenous rituximab (375 mg/m^2 weekly for 4 weeks) plus daily placebo-cyclophosphamide.<br/>
Control group received placebo-rituximab infusions plus daily cyclophosphamide (2 mg/kg per day).<br/>
Both groups were tapered off of glucocorticoids.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Remission of disease without prednisone use at 6 months.<br/>
Secondary Outcomes: Rates of disease flares, BVAS/WG score, cumulative glucocorticoid doses, rates of adverse events, and quality of life (SF-36 scores).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Long-term management, including retreatment with rituximab, was not addressed. The trial only included patients with severe ANCA-associated vasculitis who were ANCA-positive.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
National Institute of Allergy and Infectious Diseases, Genentech, Biogen, and others.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full article text and supplementary materials are available at The New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
